JP2022506072A5 - - Google Patents

Info

Publication number
JP2022506072A5
JP2022506072A5 JP2021523230A JP2021523230A JP2022506072A5 JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5 JP 2021523230 A JP2021523230 A JP 2021523230A JP 2021523230 A JP2021523230 A JP 2021523230A JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
epcam
seq
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523230A
Other languages
English (en)
Japanese (ja)
Other versions
JP7592009B2 (ja
JP2022506072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057569 external-priority patent/WO2020086665A1/en
Publication of JP2022506072A publication Critical patent/JP2022506072A/ja
Publication of JP2022506072A5 publication Critical patent/JP2022506072A5/ja
Application granted granted Critical
Publication of JP7592009B2 publication Critical patent/JP7592009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523230A 2018-10-26 2019-10-23 EpCAM抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用 Active JP7592009B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862751530P 2018-10-26 2018-10-26
US62/751,530 2018-10-26
US201962824539P 2019-03-27 2019-03-27
US62/824,539 2019-03-27
US201962846297P 2019-05-10 2019-05-10
US62/846,297 2019-05-10
PCT/US2019/057569 WO2020086665A1 (en) 2018-10-26 2019-10-23 Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022506072A JP2022506072A (ja) 2022-01-17
JP2022506072A5 true JP2022506072A5 (cg-RX-API-DMAC7.html) 2022-10-31
JP7592009B2 JP7592009B2 (ja) 2024-11-29

Family

ID=70331831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523230A Active JP7592009B2 (ja) 2018-10-26 2019-10-23 EpCAM抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用

Country Status (22)

Country Link
US (1) US20210403594A1 (cg-RX-API-DMAC7.html)
EP (2) EP4736955A3 (cg-RX-API-DMAC7.html)
JP (1) JP7592009B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210095874A (cg-RX-API-DMAC7.html)
CN (1) CN113194985A (cg-RX-API-DMAC7.html)
AU (1) AU2019364400B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007918A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117548A1 (cg-RX-API-DMAC7.html)
DK (1) DK3873512T3 (cg-RX-API-DMAC7.html)
FI (1) FI3873512T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260107T1 (cg-RX-API-DMAC7.html)
IL (1) IL282496A (cg-RX-API-DMAC7.html)
LT (1) LT3873512T (cg-RX-API-DMAC7.html)
MX (1) MX2021004808A (cg-RX-API-DMAC7.html)
PL (1) PL3873512T3 (cg-RX-API-DMAC7.html)
PT (1) PT3873512T (cg-RX-API-DMAC7.html)
RS (1) RS67852B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103949SA (cg-RX-API-DMAC7.html)
SI (1) SI3873512T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600125T1 (cg-RX-API-DMAC7.html)
TW (1) TWI897855B (cg-RX-API-DMAC7.html)
WO (1) WO2020086665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359438A1 (en) * 2021-06-21 2024-05-01 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス,インク. 活性化可能な二重アンカー型マスク化分子及びその使用方法
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
CN119630428A (zh) 2022-07-12 2025-03-14 西托姆克斯治疗公司 Epcam免疫缀合物及其用途
TW202424184A (zh) 2022-08-01 2024-06-16 美商Cytomx生物製藥公司 蛋白酶可切割部分及其使用方法
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス,インク. プロテアーゼ切断性部分及びその使用方法
US20260015425A1 (en) 2022-08-01 2026-01-15 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof
WO2026161794A1 (en) 2025-01-27 2026-07-30 Cytomx Therapeutics, Inc. Epcam immunoconjugates and therapeutic uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
WO2007027935A2 (en) 2005-08-31 2007-03-08 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
UA101142C2 (ru) * 2006-03-17 2013-03-11 Байоджэн Айдэк Ма Инк. Способ разработки антитела
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9790274B2 (en) * 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
PL3177643T3 (pl) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
SG11201701565PA (en) * 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
WO2016145349A1 (en) * 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
EP3328897A1 (en) * 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta

Similar Documents

Publication Publication Date Title
JP7191134B2 (ja) Igf-1r抗体および癌処置のためのアドレッシングビヒクルとしてのその使用
US11219693B2 (en) Antibody-drug-conjugate and its use for the treatment of cancer
AU2016344663B2 (en) Composition for the treatment of IGF-1R expressing cancer
AU2015250759B2 (en) IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
JP7579991B2 (ja) 抗ネクチン-4抗体エキサテカンコンジュゲート
WO2021136483A1 (en) Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
TWI822740B (zh) 抗her2雙互補位抗體-藥物結合物及使用方法
JP2022008618A (ja) Muc1に特異的に結合する抗体及びその用途
TW202100557A (zh) 雙互補位FR-α抗體及免疫結合物
CN113412281B (zh) Btn3a结合蛋白及其用途
JP2022512778A5 (cg-RX-API-DMAC7.html)
JP2019533719A5 (cg-RX-API-DMAC7.html)
JP2019503167A (ja) Cd38に対する抗原結合性ポリペプチド
US10400037B2 (en) Binding molecules, especially antibodies, binding to L1CAM (CD171)
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2024520188A5 (cg-RX-API-DMAC7.html)
JP7728595B2 (ja) 二重特異性抗体及びその用途
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2024523885A5 (cg-RX-API-DMAC7.html)
CN117751139A (zh) 抗Nectin-4抗体依喜替康缀合物
WO2026082125A1 (zh) 结合folr1的抗体、含有其的药物及其应用
HK40104915A (en) Multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
HK40041667A (en) Anti-her2 biparatopic antibody-drug conjugates and methods of use
HK40045878B (en) Igf-1r antibody and its use as addressing vehicle for the treatment of cancer